Optimizing Severe Asthma Care - 5/2/2019

Target Audience

This activity was developed for physicians including Eisenhower medical staff along with nurses and ancillary staff.

Learning Objectives

At the end of this presentation, participants should be better able to:

  • Explain how phenotypic, endotypic, and genetic characteristics factor into severe asthma
  • Compare and contrast biologic agents that are currently available or emerging in the treatment of severe asthma
  • Identify patients who may benefit from the use of a biologic agent for severe asthma
  • Employ a stepwise approach to incorporate novel, personalized biologic‐based treatment plans for severe asthma into the real‐world clinical setting
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
Course opens: 
05/02/2019
Course expires: 
05/02/2020
Cost:
$0.00
Parent activity set: 
Rating: 
0

Dr. Corren receives research support from Genentech, AstraZeneca, Regeneron, Sanofi, Stallergenes Greer; is a consultant for Genentech, Novartis, Regeneron, Sanofi; is on the speakers bureau for Genentech, Novartis, AstraZeneca. Dr. Corren does intend to reference unlabeled/unapproved uses of drugs or products in his presentation.

Education Planning Committee disclosures:

Mohammad Mojarad, MD (Chair): No relevant commercial interests or relationships to report
haldoun Alnabelsi, MD: No relevant commercial interests or relationships to report
Aurora L. Benson, DO; No relevant commercial interests or relationships to report
Olga Bohn, MD: No relevant commercial interests or relationships to report
Constantin Dasanu, MD, PhD: No relevant commercial interest or relationships to report
Chris Flores, MD: Speaker’s Bureau for Janssen
Raila Horne, Psy.D: No relevant commercial interests or relationships to report
Vicki Koceja, PhD, RN, FAAMA: No relevant commercial interests or relationships to report
Lisa Lindley, MD: No relevant commercial interests or relationships to report
Lester Padilla, MD: No relevant commercial interests or relationships to report
Maja Ruetschi, MD: No relevant commercial interests or relationships to report
Phil Shaver, MD: Speaker’s Bureau for Amgen
John Stansell, MD: No relevant commercial interests or relationships to report
Charles Willis, MBA: Consults for Pfizer, Inc.
Amanda Sewell, MBA: No relevant commercial interests or relationships to report
Melissa Velasquez: No relevant commercial interests or relationships to report

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance

Accreditation Period

Course opens: 
05/02/2019
Course expires: 
05/02/2020

Price

Cost:
$0.00
Please login or register to take this course.